Medicines No Longer included in the Grampian Joint Formulary
Compound alginates BNF 1.1.2
Gaviscon® Liquid 500mL NHS packs have been withdrawn by Britannia Pharmaceuticals.
Patients previously receiving Gaviscon® Liquid should be switched to Peptac®. For patients where the lower sodium content may be considered advantageous Gaviscon® Advance may be used (see 1.1). June 2005.
Gaviscon® Liquid 500mL NHS packs have been withdrawn by Britannia Pharmaceuticals.
Patients previously receiving Gaviscon® Liquid should be switched to Peptac®. For patients where the lower sodium content may be considered advantageous Gaviscon® Advance may be used (see 1.1). June 2005.
Ulcer-healing drugs BNF 1.3
Helimet® (containing lansoprazole 30mg, clarithromycin 500mg and metronidazole 400mg) discontinued in the UK. August 2005.
Expectorant and demulcent cough preparations BNF 3.9.2
Dimotane Plus® and Dimotane Plus paediatric® discontinued May 2005.
Dimotane Plus® and Dimotane Plus paediatric® discontinued May 2005.
Antipsychotic drugs BNF 4.2.1
Thioridazine (tablets). All forms of Melleril® (thioridazine) and all generic versions of thioridazine have been discontinued because the benefit/risk profile no longer meets current clinical and regulatory expectations. Any patient receiving thioridazine should be reviewed. Where patients are under the continuing care of the psychiatrists the appropriate consultant should be contacted for advice before discontinuing therapy. June 2005.
Thioridazine (tablets). All forms of Melleril® (thioridazine) and all generic versions of thioridazine have been discontinued because the benefit/risk profile no longer meets current clinical and regulatory expectations. Any patient receiving thioridazine should be reviewed. Where patients are under the continuing care of the psychiatrists the appropriate consultant should be contacted for advice before discontinuing therapy. June 2005.
Non-opioid analgesics BNF 4.7.1
Co-proxamol (tablets). The CSM has advised that Co-proxamol is to be withdrawn from the market and should no longer be prescribed. Patients should have their treatment reviewed. January 2005.
Co-proxamol (tablets). The CSM has advised that Co-proxamol is to be withdrawn from the market and should no longer be prescribed. Patients should have their treatment reviewed. January 2005.
Bisphosphonates and other drugs affecting bone metabolism BNF 6.6.2
Didronel PMO® for the treatment of osteoporosis, prevention of bone loss in post-menopausal women, and prevention and treatment of corticosteroid-induced osteoporosis. Didronel PMO® has been reclassified and is no longer recommended as a treatment choice for new patients. Didronel PMO® remains on formulary for continuation of prescribing only). May 2006
Didronel PMO® for the treatment of osteoporosis, prevention of bone loss in post-menopausal women, and prevention and treatment of corticosteroid-induced osteoporosis. Didronel PMO® has been reclassified and is no longer recommended as a treatment choice for new patients. Didronel PMO® remains on formulary for continuation of prescribing only). May 2006
Vaginal and vulval infections BNF 7.2.2
Aci-Jel® (acetic acid 0.94% vaginal gel) discontinued December 2005.
Aci-Jel® (acetic acid 0.94% vaginal gel) discontinued December 2005.
Progestogen-only contraceptives BNF 7.3.2
Microval® (tablets, levonorgestrel 30 micrograms) discontinued December 2005.
Microval® (tablets, levonorgestrel 30 micrograms) discontinued December 2005.
Electrolytes and water BNF section 9.2.2.1
Stock rationalisation - glucose 10% + 0.3% KCl infusion and infusions containing potassium chloride 0.2% are no longer stocked. Intranet info updated December 2005.
Stock rationalisation - glucose 10% + 0.3% KCl infusion and infusions containing potassium chloride 0.2% are no longer stocked. Intranet info updated December 2005.
Non-steroidal anti-inflammatory drugs BNF 10.1.1
Rofecoxib. Voluntary worldwide withdrawal of the 'COX-2 selective NSAID 'rofecoxib (Vioxx®/Vioxx® Acute) by the manufacturer. New clinical trial results showing an increased risk of confirmed serious thrombotic events (including myocardial infarction and stroke) compared to placebo, following long-term use, see CSM. September 2004.
Rofecoxib. Voluntary worldwide withdrawal of the 'COX-2 selective NSAID 'rofecoxib (Vioxx®/Vioxx® Acute) by the manufacturer. New clinical trial results showing an increased risk of confirmed serious thrombotic events (including myocardial infarction and stroke) compared to placebo, following long-term use, see CSM. September 2004.
Other anti-inflammatory preparations BNF 11.4.2
Lodoxamide eye drops have been reclassified and are no longer recommended as a treatment choice for new patients. Lodoxamide remains on formulary for continuation of prescribing only.
Lodoxamide eye drops have been reclassified and are no longer recommended as a treatment choice for new patients. Lodoxamide remains on formulary for continuation of prescribing only.
Topical corticosteroids BNF 13.4
Dermovate-NN® ointment has been discontinued, January 2006. (Dermovate-NN® cream remains available).
Dermovate-NN® ointment has been discontinued, January 2006. (Dermovate-NN® cream remains available).